HAEMOPHILIA AND OTHER CONGENITAL COAGULOPATHIESNew treatments for primary immune thrombocytopeniaMingot-Castellano, María Eva Author Information Hematology Service, Virgen del Rocío University Hospital, Seville, Spain Correspondence to María Eva Mingot-Castellano, PhD, MD, Hematology Service. Virgen del Rocío University Hospital, Seville 41013, Spain E-mail: [email protected] Received 31 March, 2021 Revised 4 September, 2021 Accepted 6 September, 2021 Blood Coagulation & Fibrinolysis: January 2022 - Volume 33 - Issue - p S8-S11 doi: 10.1097/MBC.0000000000001094 Buy Metrics Abstract Primary immune thrombocytopenia (ITP) is an autoimmune disease leading to a decreased platelet count and an ensuing haemorrhagic risk. First-line treatment against ITP consists in the administration of immunomodulators aimed at decreasing platelet destruction. Up to 70% of individuals with an ITP diagnosis treated with corticosteroids do not achieve a clinical response or demonstrate a high relapse rate, requiring treatment to prevent a haemorrhagic risk. Less than 30% of patients treated with thrombopoietin analogues, 60% of those treated with splenectomy and 20% of those treated with rituximab reach sustained remission in the absence of treatment. Because of these reasons, it is unquestionable that treatment of patients with ITP should be optimized. Through this study, we will review new actual and future options of treatment. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.